Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
01 2019
Historique:
received: 29 06 2018
revised: 07 09 2018
accepted: 11 10 2018
pubmed: 22 10 2018
medline: 12 10 2019
entrez: 22 10 2018
Statut: ppublish

Résumé

Osteosarcoma (OS) is a common, malignant musculoskeletal tumor in young people. Neoadjuvant chemotherapy has improved the survival of osteosarcoma patients but with limited benefit due to metastasis. Tumor-associated macrophages (TAMs) are involved in various mechanisms of tumor biology, which include oncogenesis, drug resistance, and tumor immune escape, as well as tumor metastasis. In this study, we proved that TAMs possess the ability to promote OS cell migration and invasion by upregulating COX-2, MMP9, and phosphorylated STAT3 and to induce the epithelial-mesenchymal transition (EMT). This evidence has also been verified in a tumor-bearing animal model, and in OS patients. Furthermore, we observed the anti-metastasis effect of COX-2 inhibition by repressing COX-2 expression, EMT-activating transcription factors and the STAT3 pathway, both in vitro and in vivo. We propose that TAMs promote OS metastasis and invasion by activating the COX-2/STAT3 axis and EMT. These findings suggest that TAMs and COX-2 may be potential targets for future anti-metastasis therapy.

Identifiants

pubmed: 30343113
pii: S0304-3835(18)30625-6
doi: 10.1016/j.canlet.2018.10.011
pii:
doi:

Substances chimiques

STAT3 Transcription Factor 0
STAT3 protein, human 0
Cyclooxygenase 2 EC 1.14.99.1
PTGS2 protein, human EC 1.14.99.1
MMP9 protein, human EC 3.4.24.35
Matrix Metalloproteinase 9 EC 3.4.24.35

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116-125

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Yu Han (Y)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.

Wei Guo (W)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China. Electronic address: bonetumor@163.com.

Tingting Ren (T)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.

Yi Huang (Y)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.

Shidong Wang (S)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.

Kuisheng Liu (K)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.

Bingxin Zheng (B)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.

Kang Yang (K)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.

Hongliang Zhang (H)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.

Xin Liang (X)

Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, People's Republic of China; Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH